RCUS
Price
$9.17
Change
+$0.11 (+1.21%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
964.26M
92 days until earnings call
TLPPF
Price
$11.20
Change
-$0.31 (-2.70%)
Updated
Aug 8 closing price
Capitalization
3.85B
Interact to see
Advertisement

RCUS vs TLPPF

Header iconRCUS vs TLPPF Comparison
Open Charts RCUS vs TLPPFBanner chart's image
Arcus Biosciences
Price$9.17
Change+$0.11 (+1.21%)
Volume$13.83K
Capitalization964.26M
Telix Pharmaceutical
Price$11.20
Change-$0.31 (-2.70%)
Volume$13.59K
Capitalization3.85B
RCUS vs TLPPF Comparison Chart in %
Loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLPPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RCUS vs. TLPPF commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a StrongBuy and TLPPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (RCUS: $9.06 vs. TLPPF: $11.19)
Brand notoriety: RCUS and TLPPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCUS: 83% vs. TLPPF: 195%
Market capitalization -- RCUS: $974.91M vs. TLPPF: $3.69B
RCUS [@Biotechnology] is valued at $974.91M. TLPPF’s [@Biotechnology] market capitalization is $3.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $96.01B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCUS’s FA Score shows that 0 FA rating(s) are green whileTLPPF’s FA Score has 0 green FA rating(s).

  • RCUS’s FA Score: 0 green, 5 red.
  • TLPPF’s FA Score: 0 green, 5 red.
According to our system of comparison, TLPPF is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCUS’s TA Score shows that 4 TA indicator(s) are bullish while TLPPF’s TA Score has 4 bullish TA indicator(s).

  • RCUS’s TA Score: 4 bullish, 5 bearish.
  • TLPPF’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both RCUS and TLPPF are a bad buy in the short-term.

Price Growth

RCUS (@Biotechnology) experienced а -1.09% price change this week, while TLPPF (@Biotechnology) price change was -14.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

RCUS is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLPPF($3.85B) has a higher market cap than RCUS($964M). TLPPF YTD gains are higher at: -25.242 vs. RCUS (-39.154). TLPPF has higher annual earnings (EBITDA): 92.5M vs. RCUS (-377M). RCUS has more cash in the bank: 997M vs. TLPPF (710M). RCUS has less debt than TLPPF: RCUS (60M) vs TLPPF (581M). TLPPF has higher revenues than RCUS: TLPPF (783M) vs RCUS (141M).
RCUSTLPPFRCUS / TLPPF
Capitalization964M3.85B25%
EBITDA-377M92.5M-408%
Gain YTD-39.154-25.242155%
P/E RatioN/A119.12-
Revenue141M783M18%
Total Cash997M710M140%
Total Debt60M581M10%
FUNDAMENTALS RATINGS
RCUS vs TLPPF: Fundamental Ratings
RCUS
TLPPF
OUTLOOK RATING
1..100
1381
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
10039
SMR RATING
1..100
9766
PRICE GROWTH RATING
1..100
6392
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (51) in the Pharmaceuticals Major industry is somewhat better than the same rating for TLPPF (86) in the null industry. This means that RCUS’s stock grew somewhat faster than TLPPF’s over the last 12 months.

TLPPF's Profit vs Risk Rating (39) in the null industry is somewhat better than the same rating for RCUS (100) in the Pharmaceuticals Major industry. This means that TLPPF’s stock grew somewhat faster than RCUS’s over the last 12 months.

TLPPF's SMR Rating (66) in the null industry is in the same range as RCUS (97) in the Pharmaceuticals Major industry. This means that TLPPF’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as TLPPF (92) in the null industry. This means that RCUS’s stock grew similarly to TLPPF’s over the last 12 months.

RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as TLPPF (100) in the null industry. This means that RCUS’s stock grew similarly to TLPPF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCUSTLPPF
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
65%
MACD
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
67%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
67%
Advances
ODDS (%)
Bullish Trend 18 days ago
80%
Bullish Trend 22 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
68%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
89%
Aroon
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLPPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FNX116.870.38
+0.32%
First Trust Mid Cap Core AlphaDEX® ETF
ZNOV26.080.06
+0.24%
Innovator Equity Defined Prt ETF -1YrNov
NUW13.71-0.02
-0.13%
Nuveen AMT-Free Municipal Value Fund
UCYB54.59-0.07
-0.13%
ProShares Ultra Nasdaq Cybersecurity
AMZZ31.16-0.09
-0.30%
GraniteShares 2x Long AMZN Daily ETF

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-2.37%
XNCR - RCUS
51%
Loosely correlated
-1.23%
IDYA - RCUS
49%
Loosely correlated
+3.08%
ACLX - RCUS
47%
Loosely correlated
-0.91%
TRDA - RCUS
47%
Loosely correlated
-2.08%
OCUL - RCUS
46%
Loosely correlated
-0.73%
More

TLPPF and

Correlation & Price change

A.I.dvisor tells us that TLPPF and BDTX have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TLPPF and BDTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLPPF
1D Price
Change %
TLPPF100%
-2.65%
BDTX - TLPPF
22%
Poorly correlated
+5.26%
ITOS - TLPPF
21%
Poorly correlated
-0.20%
RCUS - TLPPF
21%
Poorly correlated
-2.37%
ORMP - TLPPF
21%
Poorly correlated
+0.48%
ABOS - TLPPF
20%
Poorly correlated
-4.23%
More